Manufactured by Esaote S.p.A.; compact in-office MRI system, fits in a 90 ft² (8.4 m²) space and requires no shielding or special power. This low field MRI magnet is optimized for orthopedic use and imaging of the extremities.
The C-SCAN™ is developed from the ARTOSCAN™ - M with a new computer platform, and is also known as Artoscan C.
Esaote North America and Hologic Inc. are the U.S. distributors of this MRI device.

(CPMG) This type of spin echo pulse sequence consisting of a 90° radio frequency pulse followed by an echo train induced by successive 180° pulses and is useful for measuring T2 weighted images. It is a modification of the Carr-Purcell RF pulse sequence, with 90° phase shift in the rotating frame of reference between the 90° pulse and the subsequent 180° pulses in order to reduce accumulating effects of imperfections in the 180° pulses. Suppression of effects of pulse error accumulation can alternatively be achieved by switching phases of the 180° pulses by 180°.

(CPS) Sequence of a 90° RF pulse followed by repeated 180° RF pulses to produce a train of spin echoes; is useful for measuring T2.

An iron-based contrast agent with large molecular size, which prevents diffusion into body tissues and will be developed for MR imaging of the liver (taken up by macrophages), tumor microvasculature and microvessel permeability. The blood half live of the particles with 11-20 nm diameter is 3-4 hours.
At this time the development of Clariscan™ is discontinued.

See also NC100150 Injection and Ultrasmall Superparamagnetic Iron Oxide.

Combidex® is the brand name (same as Sinerem®) for an ultrasmall superparamagnetic iron oxide (USPIO) in the development pipeline to detect metastatic disease in lymph nodes. Metastatic lymph nodes show less uptake of this MRI contrast agent, which results in less signal decrease and allows the differentiation of normal lymph nodes from normal-sized, metastatic nodes. Combidex® has also potential to be used as a functional molecular imaging agent.
In March 2005, AMAG Pharmaceuticals Inc received an approvable letter from the U.S. Food and Drug Administration with respect to Combidex subject to certain conditions.
See also Ferumoxtran, Drug Development and Approval Process USA, Molecular Imaging and Classifications, Characteristics, etc.